Literature DB >> 11793449

Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines.

Hagay Sobol1, Athmane Benziane, Fabienne Kerangueven, Luo Yin, Tetsuro Noguchi, Suzanne Pauly, François Eisinger, Michel Longy, Giovanni Romeo, Gilbert Lenoir, Daniel Birnbaum.   

Abstract

The molecular biological characteristics of Burkitt lymphoma (BL), in addition to the presence of the Epstein-Barr virus (EBV) in some forms, relies on well-characterized alterations, such as MYC translocations and TP53 inactivations. To ascertain the number and location of other genome alterations, we used 191 polymorphic markers in a genome-wide search for loss of heterozygosity (LOH) in 31 Burkitt lymphoma cell lines and their normal counterparts. We were able to distinguish two types of altered allelic patterns: a bona fide LOH profile, indicative of deletion (LOH), and a profile indicative of increased dosage (ID). The former type was most frequent at chromosome arm 17p, most likely indicating TP53 gene inactivation. Increased dosage at 1q was found almost exclusively in non-EBV cell lines (P < 0.00004) and correlated well with karyotypic abnormalities affecting region 1q21-25. Our results suggest that a gene important for BL pathogenesis is located in region 1q21-25 and that the activation of this gene mimics the effects of EBV. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11793449     DOI: 10.1002/gcc.10022

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

Review 1.  Laser capture microdissection: Big data from small samples.

Authors:  Soma Datta; Lavina Malhotra; Ryan Dickerson; Scott Chaffee; Chandan K Sen; Sashwati Roy
Journal:  Histol Histopathol       Date:  2015-04-20       Impact factor: 2.303

2.  High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma.

Authors:  Saloua Toujani; Philippe Dessen; Nathalie Ithzar; Gisèle Danglot; Catherine Richon; Yegor Vassetzky; Thomas Robert; Vladimir Lazar; Jacques Bosq; Lydie Da Costa; Christine Pérot; Vincent Ribrag; Catherine Patte; Jöelle Wiels; Alain Bernheim
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

3.  FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins.

Authors:  Xing Du; Satoshi Nagata; Tomoko Ise; Maryalice Stetler-Stevenson; Ira Pastan
Journal:  Blood       Date:  2007-09-25       Impact factor: 22.113

4.  Prognostic significance of Fc receptor-like 1 in patients with chronic lymphocytic leukemia, hairy cell leukemia, and various B-cell non-Hodgkin's lymphoma.

Authors:  Zahra Yousefi; Nahid Eskandari
Journal:  Leuk Res Rep       Date:  2019-08-14

5.  Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

Authors:  Lindsay C Spender; Gareth J Inman
Journal:  Mol Cancer Res       Date:  2012-01-12       Impact factor: 5.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.